CRO for Soft Tissue Sarcoma Clinical Trials

What is a soft tissue sarcoma?

Soft tissue sarcomas are rare, aggressive, and life-threatening malignant tumors from mesenchymal origin. They can affect muscle, blood vessels, deep skin tissues, and tendons. Sarcomas can occur in almost any part of the body, although they are more frequent in the extremities.

What are the different types of soft tissue sarcomas?

There are more than 60 soft tissue sarcoma subtypes, of which the most common ones are undifferentiated pleomorphic sarcomas, synovial sarcomas, liposarcomas, and leiomyosarcomas. Other less frequent sarcomas include angiosarcomas, solitary fibrous tumor, clear cell sarcomas, and alveolar soft part sarcomas, among many others.

How many people are affected by soft tissue sarcomas?

In 2018, soft tissue sarcomas represented approximately 0.8% of all cancers in the United States. It is estimated that approximately 13-16,000 new cases and 5-6,000 deaths are attributable to sarcomas in the US each year [1].

What are the current treatments for soft tissue sarcomas?

Surgery is the standard of care for primary soft tissue sarcomas. Doxorubicin is the standard first line drug for advanced disease, while gemcitabine, docetaxel, trabectedin, pazopanib, and eribulin are options for further lines and metastatic setting. However, these drugs are not highly effective and new treatments are desperately needed.

Survival of soft tissue sarcoma patients

The 5-year overall survival rate for soft tissue sarcoma is about 65%. However, life expectancy varies depending on the stage of the cancer. The 5-year survival rate for people with metastatic sarcoma is 16% [2]. Soft tissue sarcoma patients have a highly unmet medical need.

Sofpromed: The soft tissue sarcoma expert CRO

Sofpromed is an oncology-focused CRO with wide expertise in managing cancer trials, including soft tissue sarcomas. Contact us to find out how we can help with your next soft tissue sarcoma trial.

References:

[1] Cancer statistics, 2018

[2] Life expectancy in soft tissue sarcomas